[HTML][HTML] Revisão sistemática das análises custo‐efetividade dos novos anticoagulantes orais na prevenção do acidente vascular cerebral na fibrilhação auricular
J Ferreira, A Mirco - Revista Portuguesa de Cardiologia, 2015 - Elsevier
Introdução e objetivos Os novos anticoagulantes orais são opções emergentes para a
prevenção e tratamento das doenças tromboembólicas. São cada vez mais usados na …
prevenção e tratamento das doenças tromboembólicas. São cada vez mais usados na …
[HTML][HTML] Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation
J Ferreira, A Mirco - Revista Portuguesa de Cardiologia (English Edition), 2015 - Elsevier
Introdução e objetivos Os novos anticoagulantes orais são opções emergentes para a
prevenção e tratamento das doenças tromboembólicas. São cada vez mais usados na …
prevenção e tratamento das doenças tromboembólicas. São cada vez mais usados na …
[HTML][HTML] Avaliação económica do dabigatrano na prevenção de acidentes vasculares cerebrais isquémicos em doentes com fibrilhação auricular não valvular
LS Miguel, E Rocha, J Ferreira - Revista Portuguesa de Cardiologia, 2013 - Elsevier
Introdução e objetivos Estimar os rácios custo-efetividade e custo-utilidade associados à
utilização de dabigatrano na prevenção de acidentes vasculares cerebrais e embolias …
utilização de dabigatrano na prevenção de acidentes vasculares cerebrais e embolias …
[HTML][HTML] Custo‐efetividade dos novos anticoagulantes orais na fibrilhação auricular em Portugal
Introdução e objetivos Os non‐vitamin K antagonist oral anticoagulants (NOAC) foram
recentemente comparticipados para a fibrilhação auricular não‐valvular (FA), sendo …
recentemente comparticipados para a fibrilhação auricular não‐valvular (FA), sendo …
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation
AR Kansal, Y Zheng, T Pokora, SV Sorensen - Best Practice & Research …, 2013 - Elsevier
Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …
high human and economic burden. Novel oral anticoagulants have been approved in many …
[HTML][HTML] Oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review of economic evaluations
Objectives Several studies have evaluated the economic evaluation of a group of
medications known as novel oral anticoagulant drugs (NOACs) in recent years. The aim of …
medications known as novel oral anticoagulant drugs (NOACs) in recent years. The aim of …
[HTML][HTML] Cost-effectiveness of new oral anticoagulants and warfarin in atrial fibrillation from adverse events perspective
JA Mendoza, FA Silva, LM Rangel - Revista Colombiana de Cardiologia, 2019 - Elsevier
Objective new oral anticoagulants (apixaban, dabigatran and rivaroxaban) are the newest
advance for stroke's risk reduction in atrial fibrillation. These are as effective as warfarin in …
advance for stroke's risk reduction in atrial fibrillation. These are as effective as warfarin in …
[图书][B] Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation
Background: Warfarin has been used as the only oral anticoagulant for over 50 years in
patients with atrial fibrillation. Recently new oral anticoagulants like dabigatran, rivaroxaban …
patients with atrial fibrillation. Recently new oral anticoagulants like dabigatran, rivaroxaban …
Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation
SM Singh, HC Wijeysundera - Current cardiology reports, 2015 - Springer
Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation
AR Harrington, EP Armstrong, PE Nolan Jr, DC Malone - Stroke, 2013 - Am Heart Assoc
Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …